is the chadox1 vaccine safe and immunogenic as prophylactic measure against the lethal human-coronaviruses? a systematic review

Knowledge of other coronaviruses has contributed to the development of a vaccine for the severe acute respiratory syndrome-coronavirus-2 (sars-cov-2). as soon as the genetic sequence of sars-cov-2 was released, intense global activity around different vaccine platform technologies started. among these platforms, the viral vectored chimpanzee adenovirus oxford1 (chadox1)-previously studied for various indications, including for the middle east respiratory syndrome coronavirus (mers-cov) vaccine, and currently is adapted for the chadox1 ncov-19 (novel coronavirus-19). therefore, this systematic review aimed to investigate the potential of the chadox1 platform for the development of a vaccine for sars-cov and mers-cov, the lethal human-coronaviruses (lh-covs). for this purpose, a highly sensitive literary search was conducted through electronic databases that reached 1,445 related articles, of which, eight articles were elected according to previous eligibility criteria. the gathering of the articles demonstrated that the previous approaches, referring to the chadox1 platform, have contributed to the development of vaccines against lh-covs and, that thus far, chadox1 (ncov-19 and mers) vaccines are safe and immunogenic. however, it is important to emphasize that further studies are needed to ensure the effectiveness of vaccines in humans.